Filtros de búsqueda

Lista de obras de Farhad Ravandi

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

artículo científico publicado en 2015

A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure

artículo científico publicado en 2013

A mind map for managing minimal residual disease in acute myeloid leukemia

artículo científico publicado en 2017

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

artículo científico publicado en 2013

A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia ⬇️

artículo científico publicado el 20 de agosto de 2010

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

artículo científico publicado en 2017

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2010

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2014

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

artículo científico publicado en 2013

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

artículo científico publicado en 2008

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

artículo científico publicado en 2011

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

artículo científico publicado en 2006

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

artículo científico publicado en 2010

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

artículo científico publicado en 2008

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

artículo científico publicado en 2010

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).

artículo científico publicado en 2016

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2014

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities

artículo científico publicado en 2012

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

artículo científico publicado en 2007

A potential role of ruxolitinib in leukemia

artículo científico publicado en 2011

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

artículo científico publicado en 2014

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2016

A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure

artículo científico publicado en 2013

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2017

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

artículo científico publicado en 2017

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

artículo científico publicado en 2011

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2008

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

artículo científico publicado en 2012

Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide

artículo científico publicado en 2002

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

artículo científico publicado en 2008

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

artículo científico publicado en 2007

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2017

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future.

artículo científico publicado en 2016

Acute Promyelocytic Leukemia: A Perspective.

artículo científico publicado en 2017

Acute erythroleukemia: diagnosis and management ⬇️

artículo científico publicado el 1 de diciembre de 2010

Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity

artículo científico publicado en 2012

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

artículo científico publicado en 2013

Acute myeloid leukemia as a model for cancer therapy

artículo científico publicado en 2012

Acute myeloid leukemia in the elderly: do we know who should be treated and how?

artículo científico publicado en 2013

Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features

artículo científico publicado en 2011

Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases

artículo científico publicado en 2010

Acute myeloid leukemia, version 2.2013.

artículo científico publicado en 2013

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

artículo científico publicado en 2016

Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.

artículo científico publicado en 2010

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report.

artículo científico publicado en 2017

Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.

artículo científico publicado en 2012

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2010

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemot

artículo científico publicado en 2009

Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors

scientific article published on December 2009

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

artículo científico publicado en 2015

Alemtuzumab in CLL and other lymphoid neoplasms

artículo científico publicado en 2006

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

artículo científico publicado en 2009

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia

artículo científico publicado en 2016

Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy

artículo científico publicado en 2014

An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia

artículo científico publicado en 2012

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

artículo científico publicado en 2016

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

artículo científico publicado en 2012

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

artículo científico publicado en 2010

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

artículo científico publicado en 2017

Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?

artículo científico publicado en 2014

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

artículo científico publicado en 2013

BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias

artículo científico publicado en 2008

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

artículo científico publicado en 2013

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

artículo científico publicado en 2009

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia

artículo científico publicado en 2008

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

artículo científico publicado en 2015

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count

artículo científico publicado en 2016

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia

artículo científico publicado en 2002

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

artículo científico publicado en 2013

Cellular signalling pathways: new targets in leukaemia therapy

artículo científico publicado en 2002

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

artículo científico publicado en 2018

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

artículo científico publicado en 2010

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

artículo científico publicado en 2017

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

artículo científico publicado en 2008

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

artículo científico publicado en 2014

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia

artículo científico publicado en 2014

Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia

artículo científico publicado en 2012

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

artículo científico publicado en 2015

Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.

artículo científico publicado en 2018

Chemo-immunotherapy for hairy cell leukemia ⬇️

artículo científico publicado el 21 de marzo de 2011

Chemoimmunotherapy for hairy cell leukemia

artículo científico publicado en 2015

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2010

Chemotherapy-free treatment of acute promyelocytic leukemia

artículo científico publicado en 2015

Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications

artículo científico publicado en 2003

Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment

artículo científico publicado en 2005

Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

artículo científico publicado en 2011

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

artículo científico publicado en 2016

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

artículo científico publicado en 2017

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

artículo científico publicado en 2017

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

artículo científico

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

artículo científico publicado en 2012

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

artículo científico publicado en 2014

Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens

artículo científico publicado en 2017

Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).

artículo científico publicado en 2016

Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

artículo científico publicado en 2014

Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.

artículo científico publicado en 2012

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

artículo científico publicado en 2010

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

artículo científico publicado en 2015

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

artículo científico publicado en 2006

Clofarabine combinations as acute myeloid leukemia salvage therapy

artículo científico publicado en 2008

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

artículo científico publicado en 2012

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

artículo científico publicado en 2012

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

scientific article published on 26 January 2012

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2013

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

artículo científico publicado en 2017

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

artículo científico publicado en 2015

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

artículo científico publicado en 2015

Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.

artículo científico publicado en 2018

Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.

artículo científico publicado en 2016

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

artículo científico publicado en 2005

Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis

artículo científico publicado en 2004

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

artículo científico publicado en 2015

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

artículo científico publicado en 2016

Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation.

artículo científico publicado en 2017

Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults

artículo científico publicado en 2017

Cytokines in the treatment of acute leukemias

artículo científico publicado en 2005

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

artículo científico publicado en 2009

Dasatinib, an immunomodulator? ⬇️

artículo científico publicado el 5 de agosto de 2010

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts

artículo científico publicado en 2015

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

artículo científico publicado en 2006

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

artículo científico publicado en 2018

Decitabine in older adults with acute myeloid leukemia: why was the dream broken?

artículo científico publicado en 2013

Decitabine in the treatment of myelodysplastic syndromes.

artículo científico publicado en 2010

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration ⬇️

artículo científico publicado el 24 de agosto de 2010

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

artículo científico publicado en 2016

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

artículo científico publicado en 2015

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

artículo científico publicado en 2013

Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.

artículo científico publicado en 2009

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

artículo científico publicado en 2016

Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up

artículo científico publicado en 2015

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

artículo científico publicado en 2016

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

artículo científico publicado en 2013

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

artículo científico publicado en 2013

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

artículo científico publicado en 2010

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

artículo científico publicado en 2008

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.

artículo científico publicado en 2018

Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial

artículo científico publicado en 2012

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia

artículo científico publicado en 2013

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia

artículo científico publicado en 2012

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

artículo científico publicado en 2012

Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia ⬇️

artículo científico publicado el 22 de marzo de 2011

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2012

Eradication of leukemia stem cells as a new goal of therapy in leukemia

artículo científico publicado en 2006

Eradication of minimal residual disease in hairy cell leukemia

artículo científico publicado en 2006

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2015

Expert insights into the contemporary management of older adults with acute myeloid leukemia

artículo científico publicado en 2013

Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML

artículo científico publicado en 2010

FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist

artículo científico publicado en 2017

FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

artículo científico publicado en 2011

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

artículo científico publicado en 2012

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

artículo científico publicado en 2017

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

artículo científico publicado en 2009

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

artículo científico publicado en 2008

Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant

artículo científico publicado en 2006

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin

artículo científico publicado en 2013

Feasibility of therapy with hypomethylating agents in patients with renal insufficiency

artículo científico publicado en 2010

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2015

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

artículo científico publicado en 2016

Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

artículo científico publicado en 2012

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

artículo científico publicado en 2010

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells

artículo científico publicado en 2006

Forodesine: review of preclinical and clinical data

artículo científico publicado en 2010

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis

artículo científico publicado en 2016

Frontline treatment of acute myeloid leukemia in adults

artículo científico publicado en 2016

Gemtuzumab Ozogamicin: One Size Does Not Fit All—The Case for Personalized Therapy ⬇️

artículo científico publicado el 20 de diciembre de 2010

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

artículo científico publicado en 2014

Gemtuzumab ozogamicin: time to resurrect?

artículo científico publicado en 2012

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

artículo científico publicado en 2017

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

artículo científico publicado en 2013

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

artículo científico publicado en 2017

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

artículo científico publicado en 2017

High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia

artículo científico publicado en 2007

How I manage patients with hairy cell leukaemia

artículo científico publicado en 2017

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

artículo científico publicado en 2017

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

artículo científico publicado en 2016

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

artículo científico publicado en 2011

Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia

artículo científico publicado en 2015

Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia

artículo científico

Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization

artículo científico publicado en 2014

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

artículo científico publicado en 2010

Immune defects in patients with chronic lymphocytic leukemia

artículo científico publicado en 2005

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

artículo científico publicado en 2010

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors

artículo científico publicado en 2017

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

artículo científico publicado en 2016

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2017

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2016

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

artículo científico publicado en 2012

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2018

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

artículo científico publicado en 2011

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

artículo científico publicado en 2011

Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy

artículo científico publicado en 2009

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

artículo científico publicado en 2012

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

artículo científico publicado en 2015

Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience

artículo científico publicado en 2014

Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia

artículo científico publicado en 2014

Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience

artículo científico publicado en 2009

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

artículo científico publicado en 2014

Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way?

artículo científico

Infections associated with purine analogs and monoclonal antibodies

artículo científico publicado en 2005

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2018

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

artículo científico publicado en 2012

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

artículo científico publicado en 2018

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

artículo científico publicado en 2010

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study

artículo científico publicado en 2010

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

artículo científico publicado en 2016

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

artículo científico publicado en 2014

Investigational agents in myeloid disorders

artículo científico publicado en 2004

Is acute myeloid leukemia a liquid tumor?

artículo científico publicado en 2013

Is there a standard induction regimen for patients with AML?

artículo científico publicado en 2013

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

artículo científico publicado en 2015

Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

artículo científico publicado en 2008

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

artículo científico publicado en 2014

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

scholarly article by Musa Yilmaz et al published 16 January 2019 in Blood Cancer Journal

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

artículo científico publicado en 2010

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

artículo científico publicado en 2009

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

artículo científico publicado en 2017

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

artículo científico publicado en 2018

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

artículo científico publicado en 2016

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

artículo científico publicado en 2003

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes

artículo científico publicado en 2011

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr

artículo científico publicado en 2015

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

artículo científico publicado en 2010

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

artículo científico publicado en 2016

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

scholarly article by George Z Rassidakis et al published 19 October 2018 in Blood Cancer Journal

MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation

artículo científico publicado en 2014

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

artículo científico publicado en 2011

Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

artículo científico publicado en 2016

Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions

artículo científico

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

scholarly article by Miguel A Sanz et al published 11 April 2019 in Blood

Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors

artículo científico publicado en 2011

Mature T-cell leukemias

artículo científico publicado en 2005

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

artículo científico publicado en 2015

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

artículo científico publicado en 2017

Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias

artículo científico publicado en 2010

Modern treatment programs for adults with acute lymphoblastic leukemia

artículo científico publicado en 2007

Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.

artículo científico publicado en 2003

Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?

artículo científico publicado en 2012

Monoclonal antibody therapy for hairy cell leukemia

artículo científico publicado en 2006

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

artículo científico publicado en 2017

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

scholarly article by Robert J Kreitman et al published August 2018 in Leukemia

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2012

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogene

artículo científico publicado en 2014

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

artículo científico publicado en 2013

Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor

artículo científico publicado en 2014

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.

artículo científico publicado en 2016

NCCN Clinical Practice Guidelines Acute myeloid leukemia

artículo científico publicado en 2012

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

artículo científico publicado en 2017

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

artículo científico publicado en 2007

New agents in acute myeloid leukemia and other myeloid disorders

artículo científico publicado en 2004

New treatments and strategies in acute myeloid leukemia

artículo científico publicado en 2011

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

artículo científico publicado en 2013

Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia

artículo científico publicado en 2018

Novel agents in acute myeloid leukemia.

artículo científico publicado en 2006

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

artículo científico publicado en 2019

Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma

artículo científico publicado en 2006

Novel therapeutic options for relapsed hairy cell leukemia

artículo científico publicado en 2015

Novel treatments in acute myeloid leukemia.

artículo científico publicado en 2011

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

artículo científico publicado en 2010

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

artículo científico publicado en 2013

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

artículo científico publicado en 2016

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

artículo científico publicado en 2008

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission

artículo científico publicado en 2010

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

artículo científico publicado en 2009

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

artículo científico publicado en 2011

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

artículo científico publicado en 2010

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

artículo científico publicado en 2017

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

artículo científico publicado en 2010

Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2013

Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia

artículo científico publicado en 2017

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

artículo científico publicado en 2017

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

artículo científico publicado en 2014

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

artículo científico publicado en 2018

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

artículo científico publicado en 2016

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

artículo científico publicado en 2013

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

artículo científico publicado en 2011

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

artículo científico publicado en 2016

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

artículo científico publicado en 2011

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

artículo científico publicado en 2016

Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia

scholarly article by Chi Young Ok et al published February 2019 in Haematologica

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

artículo científico publicado en 2016

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

artículo científico publicado en 2012

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

artículo científico publicado en 2006

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

artículo científico publicado en 2010

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2004

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

artículo científico publicado en 2013

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

artículo científico publicado en 2011

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

artículo científico publicado en 2016

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

artículo científico publicado en 2012

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes

artículo científico publicado en 2017

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

scholarly article by Farhad Ravandi et al published November 2018 in Haematologica

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2013

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

artículo científico publicado en 2009

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

artículo científico publicado en 2013

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

artículo científico publicado en 2015

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

artículo científico publicado en 2005

Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation

scientific article published on 14 September 2018

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

artículo científico publicado en 2010

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2015

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

artículo científico publicado en 2012

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

artículo científico publicado en 2010

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

artículo científico publicado en 2015

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

artículo científico publicado en 2015

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

artículo científico publicado en 2015

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

artículo científico publicado en 2009

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2014

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

artículo científico publicado en 2017

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

artículo científico publicado en 2014

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

artículo científico publicado en 2012

Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on October 2009

Philadelphia-positive acute lymphoblastic leukemia: current treatment options

artículo científico

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

artículo científico publicado en 2015

Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

artículo científico publicado en 2016

Potential role of sorafenib in the treatment of acute myeloid leukemia

artículo científico publicado en 2008

Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia

artículo científico publicado en 2013

Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system

artículo científico publicado en 2012

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2017

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

artículo científico publicado en 2011

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

artículo científico publicado en 2011

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

artículo científico publicado en 2010

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2010

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

artículo científico

Primary refractory acute myeloid leukaemia - in search of better definitions and therapies

artículo científico publicado en 2011

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

artículo científico publicado en 2017

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

artículo científico publicado en 2012

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

artículo científico publicado en 2015

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

artículo científico publicado en 2016

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics

artículo científico publicado en 2014

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

artículo científico publicado en 2007

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

artículo científico publicado en 2017

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin

artículo científico publicado en 2011

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

artículo científico publicado en 2015

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

artículo científico publicado en 2010

Progress in acute myeloid leukemia

artículo científico publicado en 2015

Progress in the treatment of acute myeloid leukemia

artículo científico publicado en 2007

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

artículo científico publicado en 2008

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

artículo científico publicado en 2012

Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells

artículo científico publicado en 2013

Purine analogue combinations for indolent lymphomas

artículo científico publicado en 2006

Purine analogues in advanced T-cell lymphoid malignancies

artículo científico publicado en 2006

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

artículo científico publicado en 2009

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

artículo científico publicado en 2014

Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients

artículo científico publicado en 2010

Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay

artículo científico publicado en 2012

Relapse and death during first remission in acute myeloid leukemia

artículo científico publicado en 2008

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

artículo científico publicado en 2017

Relapsed Acute Myeloid Leukemia: Need for Innovative Treatment Strategies to Improve Outcome

artículo científico publicado en 2015

Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

artículo científico publicado en 2014

Relapsed acute myeloid leukemia: why is there no standard of care?

artículo científico publicado en 2013

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

artículo científico publicado en 2015

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

artículo científico publicado en 2010

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

artículo científico publicado en 2011

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

artículo científico publicado en 2006

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

artículo científico publicado en 2009

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

artículo científico publicado en 2013

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

artículo científico publicado en 2014

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

artículo científico publicado en 2018

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

artículo científico publicado en 2008

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

artículo científico publicado en 2013

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies

artículo científico publicado en 2014

Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells

artículo científico publicado en 2004

Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on September 2011

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

scientific article published on 18 June 2015

Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia

artículo científico publicado en 2014

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

artículo científico publicado en 2017

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD

artículo científico publicado en 2013

Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate

artículo científico publicado en 2008

Senior adult oncology: three cases of advanced cancer in patients of advanced age

artículo científico publicado en 2012

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

artículo científico publicado en 2013

Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission

artículo científico publicado en 2012

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

artículo científico publicado en 2017

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

artículo científico publicado en 2011

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

artículo científico publicado en 2013

Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data

artículo científico publicado en 2013

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

artículo científico publicado en 2009

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

artículo científico publicado en 2007

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

artículo científico publicado en 2009

T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases

artículo científico publicado en 2009

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

artículo científico publicado en 2017

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

artículo científico publicado en 2016

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

artículo científico publicado en 2015

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

artículo científico publicado en 2017

Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia

artículo científico publicado en 2013

Targeting acute myeloid leukemia with TP53-independent vosaroxin

artículo científico publicado en 2016

TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation

artículo científico publicado en 2012

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

artículo científico publicado en 2013

The Search for Better Prognostic Models in Myelodysplastic Syndromes ⬇️

artículo científico publicado el 1 de marzo de 2011

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2011

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

artículo científico publicado en 2005

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

artículo científico publicado en 2014

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

artículo científico publicado en 2011

The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

artículo científico publicado en 2015

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

artículo científico publicado en 2014

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

artículo científico publicado en 2009

The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets ⬇️

artículo científico publicado el 25 de marzo de 2011

The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia

artículo científico publicado en 2012

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico

The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review

artículo científico publicado en 2016

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

artículo científico publicado en 2015

Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results

artículo científico publicado en 2012

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens

artículo científico publicado en 2009

Therapy-related acute promyelocytic leukemia

artículo científico publicado en 2011

Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy

artículo científico publicado en 2009

Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?

artículo científico publicado en 2015

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

artículo científico publicado en 2017

Time to revise the revised-International Prognostic Scoring System?

artículo científico publicado en 2015

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review

artículo científico

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

artículo científico publicado en 2011

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival

artículo científico publicado en 2008

Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options

artículo científico publicado en 2012

Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy

artículo científico publicado en 2010

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations

artículo científico publicado en 2014

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

artículo científico publicado en 2012

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

artículo científico publicado en 2013

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

artículo científico publicado en 2007

Update on the biology and treatment options for hairy cell leukemia

artículo científico publicado en 2014

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

artículo científico publicado en 2007

Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia

artículo científico publicado en 2014

Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

artículo científico publicado en 2012

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2017

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

artículo científico publicado en 2015

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?

artículo científico publicado en 2017

mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia

artículo científico publicado en 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda